The purpose of the study is to compare how the medicine moves through the body when taken as a capsule without food and when taken as a tablet both with and without food. The study will also assess whether the medicine is safe and well-tolerated in healthy volunteers. This is a crossover study, which means that each person will receive the medicine in different forms and under different conditions during separate treatment periods.

During the study, participants will receive the medicine by mouth in three different ways across three separate periods. Blood and urine samples will be collected to measure the amount of medicine in the body over time. Safety will be monitored throughout the study by checking physical health, body weight, any side effects that occur, laboratory test results from blood and urine samples, blood pressure and heart rate measurements, and heart activity using an electrocardiogram, which is a test that records the electrical signals of the heart.

The purpose of the study is to compare the effectiveness of a Mediterranean diet combined with intermittent fasting to the medication Mysimba in improving liver fibrosis. Participants will follow one of these two treatments for six months. The Mediterranean diet is known for its focus on fruits, vegetables, whole grains, and healthy fats, and in this study, it will be combined with a method called intermittent fasting, where eating is restricted to certain times of the day. The study will measure changes in liver fibrosis using a method called *FibroScan*, which checks how stiff the liver is, as well as other health factors like body weight, cholesterol levels, and blood sugar.

Participants in the study will be adults aged 18 to 75 who have type 2 diabetes and a *Body Mass Index (BMI)* of 27 or higher, indicating they are overweight or obese. The study will also look at other aspects of health, such as physical activity, sleep patterns, and quality of life, to see how these treatments might affect overall well-being. The goal is to find out which treatment is more effective in improving liver health in people with type 2 diabetes and excess weight.

The purpose of the study is to see if simvastatin can significantly reduce liver fibrosis in patients with chronic liver disease due to alcohol. Participants will receive either simvastatin or a placebo and will be monitored over a period of 24 months. During this time, the health of their liver will be assessed through various methods, including liver biopsies, which involve taking a small sample of liver tissue to examine under a microscope. The study will also look at changes in liver stiffness, which can be measured using special imaging techniques, and other markers in the blood that indicate liver health.

Throughout the study, researchers will also explore other aspects of liver health, such as changes in the gut microbiome, which is the community of bacteria living in the intestines, and markers of inflammation in the body. The safety and any side effects of simvastatin will be closely monitored to ensure the well-being of participants. This trial is designed to provide valuable insights into whether simvastatin can be a beneficial treatment for reducing liver damage in patients with alcoholic liver disease.

Participants in the study will receive either Efruxifermin or a placebo, which is a substance with no active medication. Efruxifermin is given as a solution for injection, meaning it is administered through a needle under the skin. The study will last for about 52 weeks, during which participants will have regular check-ups to monitor their liver health and overall well-being. The main goal is to see if Efruxifermin can help resolve NASH/MASH and reduce fibrosis by the end of the study period.

The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving Efruxifermin and who is receiving the placebo. This helps ensure that the results are unbiased. The trial will also evaluate the safety of Efruxifermin, looking at any side effects that may occur. By the end of the study, researchers hope to determine if Efruxifermin is an effective treatment option for people with NASH/MASH and fibrosis.

Participants in the study will be randomly assigned to receive either nicotinamide or a placebo, which is a substance with no active medication. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are unbiased. The study will last for 12 months, during which various health measurements will be taken to assess changes in liver health and other related factors.

Throughout the study, researchers will monitor changes in liver stiffness, the amount of fat in the liver, and other health indicators. These measurements will help determine if nicotinamide can improve liver health and manage symptoms of type 2 diabetes. The study aims to provide valuable insights into the potential benefits of nicotinamide for patients with these conditions.